The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of temsirolimus and erlotinib in patients (pts) with recurrent/metastatic (R/M), platinum-refractory head and neck squamous cell carcinoma (HNSCC).
Julie E. Bauman
Research Funding - Genentech; Pfizer
Hugo Arias-Pulido
No relevant relationships to disclose
Sang-Joon Lee
No relevant relationships to disclose
Michael Considine
No relevant relationships to disclose
M Houman Fekrazad
No relevant relationships to disclose
Jason Howard
No relevant relationships to disclose
Justin A. Bishop
No relevant relationships to disclose
Garth T Olson
No relevant relationships to disclose
Dennie V. Jones
Consultant or Advisory Role - Roche/Genentech
Elana J. Fertig
No relevant relationships to disclose
Christine H. Chung
Research Funding - Bayer